pRRopheticCV: This function uses X fold cross validation on the TrainingSet...
In xlucpu/MOVICS: Multi-Omics integration and VIsualization in Cancer Subtyping

Description Usage Arguments Value Author(s)

This function does cross validation on a training set to estimate prediction accuracy on a training set. If the actual test set is provided, the two datasets can be subsetted and homogenized before the cross validation analysis is preformed. This may improve the estimate of prediction accuracy.

pRRopheticCV(
  drug,
  tissueType = "all",
  testExprData = NULL,
  cvFold = -1,
  powerTransformPhenotype = TRUE,
  batchCorrect = "eb",
  removeLowVaryingGenes = 0.2,
  minNumSamples = 10,
  selection = 1
)

`drug`	the name of the drug for which you would like to predict sensitivity, one of A.443654, A.770041, ABT.263, ABT.888, AG.014699, AICAR, AKT.inhibitor.VIII, AMG.706, AP.24534, AS601245, ATRA, AUY922, Axitinib, AZ628, AZD.0530, AZD.2281, AZD6244, AZD6482, AZD7762, AZD8055, BAY.61.3606, Bexarotene, BI.2536, BIBW2992, Bicalutamide, BI.D1870, BIRB.0796, Bleomycin, BMS.509744, BMS.536924, BMS.708163, BMS.754807, Bortezomib, Bosutinib, Bryostatin.1, BX.795, Camptothecin, CCT007093, CCT018159, CEP.701, CGP.082996, CGP.60474, CHIR.99021, CI.1040, Cisplatin, CMK, Cyclopamine, Cytarabine, Dasatinib, DMOG, Docetaxel, Doxorubicin, EHT.1864, Elesclomol, Embelin, Epothilone.B, Erlotinib, Etoposide, FH535, FTI.277, GDC.0449, GDC0941, Gefitinib, Gemcitabine, GNF.2, GSK269962A, GSK.650394, GW.441756, GW843682X, Imatinib, IPA.3, JNJ.26854165, JNK.9L, JNK.Inhibitor.VIII, JW.7.52.1, KIN001.135, KU.55933, Lapatinib, Lenalidomide, LFM.A13, Metformin, Methotrexate, MG.132, Midostaurin, Mitomycin.C, MK.2206, MS.275, Nilotinib, NSC.87877, NU.7441, Nutlin.3a, NVP.BEZ235, NVP.TAE684, Obatoclax.Mesylate, OSI.906, PAC.1, Paclitaxel, Parthenolide, Pazopanib, PD.0325901, PD.0332991, PD.173074, PF.02341066, PF.4708671, PF.562271, PHA.665752, PLX4720, Pyrimethamine, QS11, Rapamycin, RDEA119, RO.3306, Roscovitine, Salubrinal, SB.216763, SB590885, Shikonin, SL.0101.1, Sorafenib, S.Trityl.L.cysteine, Sunitinib, Temsirolimus, Thapsigargin, Tipifarnib, TW.37, Vinblastine, Vinorelbine, Vorinostat, VX.680, VX.702, WH.4.023, WO2009093972, WZ.1.84, X17.AAG, X681640, XMD8.85, Z.LLNle.CHO, ZM.447439.
`tissueType`	specify if you would like to traing the models on only a subset of the CGP cell lines (based on the tissue type from which the cell lines originated). This be one any of "all" (for everything, default option), "allSolidTumors" (everything except for blood), "blood", "breast", "CNS", "GI tract" ,"lung", "skin", "upper aerodigestive"
`testExprData`	The test data where the phenotype will be estimted. It is a matrix of expression levels, rows contain genes and columns contain samples, "rownames()" must be specified and must contain the same type of gene ids as "trainingExprData".
`cvFold`	Specify the "fold" requried for cross validation. "-1" will do leave one out cross validation (LOOCV)
`powerTransformPhenotype`	Should the phenotype be power transformed before we fit the regression model? Default to TRUE, set to FALSE if the phenotype is already known to be highly normal.
`batchCorrect`	How should training and test data matrices be homogenized. Choices are "eb" (default) for ComBat, "qn" for quantiles normalization or "none" for no homogenization.
`removeLowVaryingGenes`	What proportion of low varying genes should be removed? 20 percent by default.
`minNumSamples`	How many training and test samples are requried. Print an error if below this threshold
`selection`	How should duplicate gene ids be handled. Default is -1 which asks the user. 1 to summarize by their or 2 to disguard all duplicates.

An object of class "pRRopheticCv", which is a list with two members, "cvPtype" and "realPtype", which correspond to the cross valiation predicted phenotype and the user provided measured phenotype respectively.

Paul Geeleher, Nancy Cox, R. Stephanie Huang

xlucpu/MOVICS documentation built on July 24, 2021, 9:23 p.m.